Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTENSA: Dupilumab and Berahyaluronidase Alfa Coformulation in Atopic Dermatitis
NCT07919899Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Nov 2026
- Primary completion
- May 2028
01
Overview
Phase 3, randomised, open-label trial in atopic dermatitis (AD) comparing Dupilumab coformulated with berahyaluronidase alfa with Dupilumab approved formulation (2 arms). Primary endpoint: Trough Concentration at Steady State at 20 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dupilumabtergase
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07919899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919899.